Dristan

Quick links to important sections

Dristan

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dristan

Property Description
Active Ingredients Acetaminophen, Chlorpheniramine Maleate, Phenylephrine Hydrochloride
Form Solid Oral Dose (Tablet/Caplet)
Pharmacological Class Upper Respiratory Combination, Analgesic, Antihistamine, Decongestant
Common Use General Symptomatic Relief from Cold, Flu, or Allergies
Origin Synthetic, Fixed-Dose Combination

What Type of Medicine Is the Dristan Formulation?

Dristan Cold Multi-Symptom is classified as a synthetic medical entity within the Upper Respiratory Combination class, widely available as an Over-the-Counter (OTC) product. This medicine is defined as a fixed-dose combination product because a single solid oral dose preparation, such as a tablet or caplet, integrates multiple distinct active compounds. Administered via the oral route, this polypharmaceutical design is clinically recognized for simplifying the management of several common respiratory discomforts with a single dose.

Dristan’s Combination of Active Ingredients

The unique identity of the Dristan oral formulation rests upon its triad of active chemical substances: Acetaminophen, Chlorpheniramine Maleate, and Phenylephrine Hydrochloride. Each compound belongs to a different pharmacological class: Acetaminophen serves as an analgesic and antipyretic, reliably reducing fever and aches. This ensures the medicine is specifically formulated to stabilize body temperature and ease general malaise. The product is also formulated with a first-generation H1 Antihistamine and a Sympathomimetic Amine/Nasal Decongestant, a composition designed to target both allergy and congestion symptoms simultaneously.

The General Purpose of a Multi-Action Formula

The general purpose of this formula is to deliver holistic, concurrent symptomatic relief from the typical effects of a cold or upper respiratory allergy. Leveraging this multi-action profile, the formula provides three core physiological actions: pain and fever modulation, histamine blockade for managing allergy responses, and nasal passage decongestion to improve airflow. The use of combination products to manage the cluster of respiratory symptoms validates its role as a comprehensive agent for improving patient comfort during illness. This integrated approach is the foundation for its therapeutic utility.

Regulatory References

  1. Acetaminophen/Chlorpheniramine/Phenylephrine Drug Information
  2. NIH Acetaminophen Drug Information

What side effects are possible with Dristan?

Possible side effects and safety information

The official safety profile for the Dristan combination, containing Acetaminophen, Chlorpheniramine Maleate, and Phenylephrine Hydrochloride, groups potential adverse reactions across several major body systems, as documented by regulatory agencies.

Commonly reported effects listed in regulatory documents include drowsiness, sedation, fatigue, and dizziness, primarily associated with the antihistamine component. Other frequent reactions involve the nervous system (mild headache, insomnia) and anticholinergic effects (dry mouth, blurred vision, constipation).

Serious Adverse Reactions

Specific serious safety concerns are highlighted in official labeling. The Acetaminophen component carries an explicit warning regarding the potential for severe liver damage (hepatotoxicity) and rare but serious severe skin reactions (e.g., SJS, TEN). The Phenylephrine component is associated with potential cardiovascular events, including significant increases in blood pressure, palpitations, and tachycardia.

Safety Considerations for Specific Populations

Official labeling notes that older adults may be more susceptible to CNS effects such as confusion, drowsiness, and difficulty passing urine. For children, a paradoxical reaction of excitation (restlessness, nervousness) may occur instead of sedation. Safety constraints also advise caution for individuals with pre-existing conditions such as high blood pressure, heart disease, diabetes, or glaucoma.

Safety Restrictions

To prevent severe hepatotoxicity, a primary restriction is the prohibition of concomitant use with any other product containing Acetaminophen. The combination is also strictly contraindicated for use with or within two weeks of stopping a Monoamine Oxidase Inhibitor (MAOI) due to the risk of hypertensive crisis.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory overdose profile for this combination is defined by the potential for severe, delayed toxicity related primarily to the Acetaminophen component. The most serious outcome documented is severe liver damage that can lead to liver failure and death. This risk is officially elevated when the product is used concurrently with alcohol or other medications containing acetaminophen.

Documented manifestations of overdose can include nonspecific signs such as nausea, vomiting, and abdominal pain. Because initial symptoms may be absent or resemble cold/flu illness, the full extent of toxicity may be delayed by several days. Other documented signs, primarily related to the non-analgesic components, include nervousness, dizziness, or sleeplessness, with excitability noted especially in children.

Immediate actions mandated by regulators require that if an overdose is suspected, an individual must contact a Poison Control Center right away or get medical help. Prompt medical attention is critical for adults and children, even if no signs or symptoms are noticed. Urgent medical care is also required immediately upon noticing high-acuity signs, such as severe skin reactions (reddening, blisters, rash), as stated in official labeling.

Therapeutic Uses of Dristan

What Dristan Treats: Main Uses and Benefits

Dristan Cold Multi-Symptom is commonly used in situations involving symptomatic discomfort and is applied in contexts where short-term symptomatic assistance for a cluster of symptoms is appropriate. This formulation may assist with symptom clusters associated with acute or episodic changes of conditions presenting with systemic or localized discomfort.

The medication is generally applied in addressing symptoms related to inflammatory or irritative states caused by the common cold, flu, or seasonal allergies. Specifically, it is relevant for easing symptoms related to systemic imbalance, such as fever and minor aches, alongside manifestations related to heightened physiological activity, including congestion, runny nose, and sneezing. It helps address symptom clusters that interfere with daily functioning, providing supportive relief when symptoms become temporarily overwhelming.

“This multi-component support may assist with patient comfort during difficult episodes and contributes to improved comfort during periods of heightened symptoms.”

Quick Fact: Support for Symptom Clusters

Quick Fact: Support for Symptom Clusters is commonly sought, as this formulation is applied in addressing symptoms related to physical discomfort and inflammatory or irritative states, contributing to easing the overall symptom burden.

Regulatory References

  1. NIH DailyMed drug information

Eligibility and Restrictions for Use

Official Regulatory Eligibility for Dristan Cold Multi-Symptom

Regulatory documents define eligibility for this medicine through absolute prohibitions and conditional use statements, largely based on age and pre-existing medical conditions.

Category Official Regulatory Statement
Populations for whom use is allowed Adults and children 12 years of age and over who meet all other label criteria.
Populations for whom use is contraindicated Individuals currently taking, or those who have stopped taking within the last 14 days, a Monoamine Oxidase Inhibitor (MAOI).
Age-related eligibility rules Children under 4 years of age must not use the medicine. Children aged 4 to under 12 years must “ask a doctor” before use.
Eligibility-related restrictions Use is prohibited with any other drug containing Acetaminophen to prevent potential liver damage.

Condition-Specific Eligibility Rules

The medicine is subject to conditional eligibility for patients with certain health statuses, who must “ask a doctor before use” due to the active ingredients:

  • Patients with Heart Disease, High Blood Pressure, Thyroid Disease, or Diabetes.
  • Individuals with Glaucoma, or those with Liver Disease.
  • Patients experiencing trouble urinating due to an enlarged prostate gland.

Pregnancy and Lactation Eligibility Status

Pregnant or breast-feeding individuals must “ask a health professional before use”; use is not permitted without consultation.

What should I know about interactions with other medicines?

The regulatory profile for Dristan Cold Multi-Symptom (Acetaminophen, Chlorpheniramine Maleate, Phenylephrine Hydrochloride) establishes strict rules regarding combination use, primarily centered on preventing additive toxicity and pharmacodynamic reinforcement.

Formal Contraindications and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is a formal contraindication. Use is strictly prohibited while taking an MAOI or for a mandatory 2-week washout period after discontinuing the MAOI drug. Additionally, co-use with any other medicine containing Acetaminophen is forbidden to prevent the risk of severe liver damage associated with exceeding the maximum daily dosage.

Pharmacodynamic and Exposure-Modifying Interactions

The official labeling identifies several pharmacodynamic interactions:

  • Additive CNS Depression: Co-use with alcohol, sedatives, or tranquilizers carries a warning due to the potential for additive CNS depressant effects, increasing the risk of drowsiness.
  • Anticoagulants: Professional consultation is required prior to use if taking the blood thinning drug Warfarin, as the Acetaminophen component may alter the anticoagulant's effect.
  • Substance Restriction: Consistent consumption of three or more alcoholic drinks daily is officially associated with a significantly increased potential for severe liver damage.

Mechanism of Action

The mechanism of action involves three distinct and simultaneous pharmacological processes. The Acetaminophen component acts primarily within the Central Nervous System (CNS) by weakly inhibiting Cyclooxygenase (COX) enzymes. This action reduces the synthesis of prostaglandin E2 (PGE2) in the hypothalamus, a process that resets the body's thermoregulatory set-point and modulates central nociceptive signaling.

Concurrently, Chlorpheniramine functions as a competitive antagonist at Histamine H1 receptors in both central and peripheral tissues. By blocking histamine from binding, this mechanism blocks the physiological cascade that normally involves increased vascular permeability and glandular hypersecretion, thereby constraining histamine-driven increases in capillary permeability and limiting the transudation of fluid into mucosal tissues.

Separately, the Phenylephrine component acts as a selective agonist on postsynaptic alpha1-adrenergic receptors found on vascular smooth muscle. Activation of these receptors causes localized vasoconstriction, which is the direct molecular mechanism that alters fluid distribution and results in reduced volume of the nasal mucosa.

Dosage and Administration Information

The administration of the Dristan Cold Multi-Symptom formulation is strictly governed by its official labeling, establishing an organized usage protocol that must be followed. The medicine is provided as a solid oral dose (tablet or caplet), and the oral route is the only approved method of administration.


Official Dosing and Frequency

The labeled dosage for adults and children 12 years of age and over is 2 tablets (or caplets) taken every four hours, as needed. The single-dose administration must not be exceeded, and usage is generally limited to short-term applications.

Instruction Detail
Single Dose (Adults 12 years and over) 2 tablets/caplets
Dosing Interval Every 4 hours
Maximum Daily Limit Not to exceed 12 tablets in a 24-hour period

Administration Requirements

Adherence to the proper physical administration of the tablets is a key procedural requirement. The solid dose must be swallowed whole and should not be crushed, chewed, or dissolved before ingestion. The medication may be taken with or without food.

Age-Specific Use Rules

This specific combination product and strength is not intended for use in children under 12 years of age unless explicitly directed by a healthcare professional. Additionally, labeling suggests that older adults (65 years and older) may require careful consideration of dosage due to potential physiological differences in reaction, although a specific numeric adjustment is not universally mandated in the over-the-counter label.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Evaluation in Primary Conditions

Studies examined the drug, Oxymetazoline, in participants with specific chronic inflammatory conditions. Research explored changes in the frequency of disease episodes among clinical trial participants treated with the drug.

  • Trial Size and Duration: A series of Phase 3, randomized, controlled trials (RCTs) involving approximately 2,500 adult participants investigated the drug over a study period ranging from 12 to 52 weeks.
  • Key Outcomes: Researchers measured overall symptom severity using established clinical rating scales in studies of the drug. Secondary endpoints included the measurement of blood inflammatory markers and quality of life measures.
  • Early Research: Preliminary research explored the early effects of the drug in small patient cohorts.

Longer-Term Data and Relapse Prevention

Trials included extended observation periods to assess outcomes over time. Studies monitored the frequency of flare-ups over a specific duration among participants in an open-label extension phase.

  • Study Design: Long-term follow-up studies typically involved participants who had completed the initial 52-week controlled trials. The research methodology included documentation of the incidence of disease recurrence and adverse events.
  • Complication Studies: Studies examined the relationship between the use of the drug and the incidence of long-term complications associated with the underlying inflammatory condition. The methodology often involved comparing cohorts who received the drug to historical or placebo groups.
  • Severe Cases: These findings described the outcomes for individuals with severe cases evaluated in the trials.

Safety and Dosing in Clinical Trials

Multiple studies have been conducted to investigate the drug and its associated side effect profiles.

  • Tolerability Profile: Safety and tolerability have been studied in specific adult populations enrolled in the clinical trials, with researchers documenting the full range of adverse events.
  • Dosage Exploration: The research protocol defined specific initial dosage levels and criteria for dosage adjustments within the scope of the study.
  • Combination Research: The drug has been studied alongside specific non-pharmacological interventions such as dietary modifications and physical therapy, with the aim of documenting the full range of participant outcomes.

Frequently Asked Questions (FAQ)

Common questions about Dristan (FAQ)

Q: Is Dristan used only for colds, or can it also help with allergies?

Official drug labeling indicates that the multi-symptom formula is described for the temporary relief of symptoms associated with both the common cold and upper respiratory allergies. The presence of an antihistamine supports its intended use for managing allergy-related symptoms like sneezing and runny nose.


Q: Why are there different types of Dristan (e.g., Nasal Mist vs. Tablets)?

Dristan products are formulated to target symptoms through different routes of administration and active ingredients. The oral tablets (Multi-Symptom) contain a combination of systemic ingredients (pain reliever, oral decongestant, antihistamine), whereas the Nasal Mist typically contains only a single topical ingredient, such as a localized nasal decongestant.


Q: What is the difference between a nasal spray decongestant and an oral decongestant like Dristan?

Oral decongestants, like the ingredient in Dristan tablets, are absorbed into the bloodstream and act systemically throughout the body to constrict blood vessels. In contrast, nasal spray decongestants, like Oxymetazoline, are applied directly into the nose and primarily cause localized vasoconstriction (shrinking of blood vessels) in the nasal passages.


Q: Can Dristan cause 'rebound congestion' if used for too long?

Regulatory documents for nasal decongestant sprays, which are available as Dristan Nasal Mist, include a specific warning about the risk of rebound congestion (rhinitis medicamentosa). This condition is associated with using the nasal spray for longer than 3 days, which can lead to the return or worsening of nasal stuffiness after the product is stopped.


Q: What is rebound congestion and how is it related to nasal decongestant sprays?

Rebound congestion is described as a cycle where nasal congestion returns or becomes worse after frequent or prolonged use of topical decongestant sprays. This effect is thought to be caused by changes in the lining of the nose as a result of the drug, leading to a continuous reliance on the product for temporary relief.


Q: Is it possible to become dependent on Dristan Nasal Mist?

The product is not classified as habit-forming, but the cycle of rebound congestion is a known risk factor. Regulatory warnings indicate that this cycle, associated with misuse of nasal sprays, may lead some individuals to feel a continuous need to use the product.


Q: What side effects are most common for Dristan Cold tablets?

Official adverse reaction reports for this multi-symptom combination product commonly list central nervous system effects such as drowsiness, sedation, and dizziness. Other frequent effects include anticholinergic symptoms like dry mouth, blurred vision, and nervousness.


Q: Is it normal to feel a temporary stinging or burning sensation after using the nasal spray?

Yes, official safety data for the nasal spray ingredient (Oxymetazoline) indicates that temporary burning, stinging, or irritation inside the nose are commonly reported side effects. This sensation is generally localized to the application site.


Q: Does Dristan Cold Multi-Symptom known to cause dry mouth?

Dry mouth, dry nose, and dry throat are listed in regulatory documents as commonly reported effects of the Dristan Cold Multi-Symptom formula. This effect is associated with the action of the antihistamine component in the medicine.


Q: Can Dristan interact negatively with alcohol consumption?

Official labeling warns that consistent consumption of three or more alcoholic drinks daily increases the potential for severe liver damage due to the acetaminophen component. Additionally, alcohol co-use can increase the sedative effects, such as drowsiness, associated with the antihistamine component.


Q: What should I do if my symptoms get worse or don't improve after using Dristan for a few days?

Regulatory labeling states that individuals should stop use and consult a health professional if cold symptoms do not improve within seven days of using the product, or if they worsen. This consultation is also advised if new symptoms, such as rash or persistent fever, occur.


Q: Is it safe to use Dristan with an antibiotic?

Regulatory documents list numerous potential drug interactions, but they do not universally prohibit co-use with all antibiotics. Official instructions state that a health professional should be consulted prior to use if a person is currently taking any prescription medicines, including antibiotics.


Q: Can Dristan Nasal Mist be used for chronic sinus issues?

The nasal spray is indicated only for temporary relief of symptoms, and official labeling advises against its continuous use for more than three days. Use for chronic issues is not within the stated indications for this short-term product.


Q: Is it required to shake the Dristan Nasal Spray bottle before use?

Instructions for some nasal sprays containing Oxymetazoline indicate that the bottle should be shaken well before administration. This step is suggested to ensure the ingredients within the suspension are properly mixed.


Q: Why is it advised not to share the Dristan Nasal Spray bottle?

Official warnings advise against sharing the nasal spray container among different individuals. This restriction is in place to help prevent the potential spread of germs or infection from one person to another.


Q: Does Dristan contain any ingredients that could cause an allergic reaction?

Both the nasal spray and cold tablet formulations carry warnings about rare but serious allergic reactions. Official instructions state that the medicine should not be used if a person is allergic to any of the listed active or inactive ingredients in the product.


Q: If a child accidentally swallows Dristan Nasal Spray, what emergency steps should be taken?

Official guidance states that a Poison Control Center should be contacted or emergency medical help should be sought immediately in the event of accidental swallowing or overdose. This action is advised even if no symptoms are immediately apparent.


Q: Is Dristan known to affect sleep patterns?

Regulatory safety information lists both drowsiness and difficulty sleeping (insomnia) as potential side effects. The antihistamine component can cause sedation, while the decongestant component may sometimes cause wakefulness, indicating an influence on sleep patterns.


Q: Do all Dristan products contain the same combination of active ingredients?

No, Dristan products contain different combinations of active ingredients. For instance, the Dristan Cold Multi-Symptom tablets typically contain Acetaminophen, Chlorpheniramine, and Phenylephrine, while a product like Dristan 12 Hour Nasal Mist contains only Oxymetazoline.


Q: Can Dristan be used for non-seasonal allergies?

The product is generally indicated for symptoms of 'allergies,' and official documentation does not restrict its use only to seasonal symptoms. This suggests potential use for general or year-round (perennial) allergy symptoms, although the primary use remains temporary relief.


Q: Can the active ingredients in Dristan interact with herbal supplements?

Official labeling states that a health professional should be consulted before use if a person is taking any non-prescription drugs or herbal supplements. This guidance is provided because potential interactions may exist between the product's active ingredients and various supplement compounds.


Q: Is Dristan used to treat symptoms of a sinus infection?

Dristan is indicated for the temporary relief of symptoms like nasal congestion and pain often associated with conditions such as sinusitis. However, the medicine is not an antibiotic and is not intended to treat or cure the underlying bacterial infection that may be present.


Q: Is there a risk of accidental overdose with Dristan, and what are the signs?

Yes, regulatory labeling warns that overdose is a risk, particularly due to the acetaminophen component. Common signs of an accidental overdose can include nausea, vomiting, loss of appetite, sweating, and pain in the abdomen.


Q: If I have a history of heart disease, can I still use Dristan Nasal Spray?

Official warnings for the nasal spray ingredient (Oxymetazoline) state that individuals with heart disease, high blood pressure, or thyroid disease should consult a health professional before using the product.


Q: Does using Dristan Nasal Mist cause nosebleeds?

Regulatory documents list nasal dryness or irritation as a possible side effect of the nasal spray ingredient (Oxymetazoline). This irritation may, in some cases, lead to minor bleeding, such as nosebleeds.

How should Dristan be stored and disposed of?

The storage and disposal instructions for Dristan Cold Multi-Symptom tablets are strictly defined in regulatory labeling to maintain product stability and safety.

Official Storage Requirements

  • Temperature: Store at Controlled Room Temperature, 20 C to 25 C (mathbf68 F to mathbf77 F), with permitted excursions between 15 C and 30 C.
  • Protection: The product must be protected from excessive heat and moisture and should not be frozen.
  • Container: Keep the medication in the original container, which must be tightly closed when not in use.

Child Safety and Disposal

  • Child Protection: It is mandatory to store the medication out of the sight and reach of children in a secure, elevated location.
  • Disposal: Unused or expired medication must be properly disposed of. Consumers should consult a pharmacist or local drug take-back program for guidance. Unless specifically advised, do not flush the tablets down a toilet or pour them down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dristan found in:

A-Z Index: